|
| Exchange Disseminated Time | The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in Economic Times on December 31, 2014 titled "Wockhardt, Cadila & Hospira voluntarily recall drugs in US."
Cadila Healthcare Ltd replied stating "the recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact.
This is the same product for which we had made the clarification vide our letter dated 17.12.2014" |
|
|